Home › Companies › IMMUNOGEN INC. › 2023-2024

IMMUNOGEN INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and IMMUNOGEN INC.’s Form 8-K, filed 2024-01-31 (Item 5.07 on EDGAR). Page generated 04 October 2026.

5Reported items
337Asset managers
1,159Fund votes
2024-01-31Meeting date

Proxy season: 2023-2024

Explore IMMUNOGEN INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by IMMUNOGEN INC.

These tallies are IMMUNOGEN INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-01-31 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IMMUNOGEN INC. — official shareholder meeting results, meeting held 2024-01-31
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Proposal 1: Proposal to approve the Agreement and Plan of Merger, dated November 30, 2023 (as may be amended, modified or supplemented from time to time, the "Merger Agreement"), by and among ImmunoGen, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Su	208,162,925	3,052,370	3,305,231	--	--	Passed
Proposal 2: Proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to ImmunoGen's named executive officers that is based on or otherwise related to the Merger Agreement and the transactions contemplated by th	89,631,125	120,475,005	4,414,396	--	--	Failed

This meeting is also recorded here as 2024-02-01; both records come from the same filing, so the date should be checked against it.

Source: IMMUNOGEN INC., Form 8-K, filed with the SEC on 2024-01-31 — read the filing on EDGAR.

How asset managers voted at the IMMUNOGEN INC. 2023-2024 meeting

Each item below shows how the 337 asset managers that disclosed a IMMUNOGEN INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of IMMUNOGEN INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. A proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to ImmunoGen's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement; and

SECTION 14A SAY-ON-PAY VOTESCompany result: Failed

Combines 21 wordings of this item as funds reported it.

43% Failed · of votes cast

FOR 43%AGAINST 57%

FOR: 89,631,125AGAINST: 120,475,005

IMMUNOGEN INC.’s own tally for this item (“Proposal 2: Proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to ImmunoGen's named executive officers that is based on or otherwise related to the Merger Agreement”): 89,631,125 for, 120,475,005 against — failed, per its Form 8-K filed 2024-01-31 (Item 5.07). Of all 265,842,000 outstanding shares: 34% for, 45.3% against (79% of the company cast a for/against vote).

The 324 asset managers below cast 31% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 30%AGAINST 66%

FOR: 30.0%AGAINST: 65.9%ABSTAIN: 4.1%NOT VOTED: 0.1%

Largest asset managers voting on “A proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable t” at IMMUNOGEN INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
New York Life	0	41,693,003	0	Against
Vanguard	89,900	25,463,237	0	Against
RA CAPITAL MANAGEMENT, L.P.	23,716,326	0	0	For
BlackRock	45,777	20,147,269	0	Against
Redmile Group, LLC	16,423,922	0	0	For
Fidelity	0	11,035,325	0	Against
State Street	3,215	9,820,777	0	Against
Janus Henderson	2,440,627	587,193	5,614,708	Abstain
Fairmount Funds Management LLC	5,929,592	0	0	For
JANUS INVESTMENT FUND	2,322,958	0	2,799,857	Abstain
GEODE CAPITAL MANAGEMENT, LLC	0	4,980,248	0	Against
Man Group plc	0	4,100,720	0	Against
Charles Schwab	0	3,784,892	0	Against
Pentwater Capital Management LP	0	3,657,799	0	Against
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP	3,252,001	0	0	For
MAVERICK CAPITAL LTD	2,503,627	0	0	For
DE Shaw	0	2,290,288	0	Against
TIG Advisors, LLC	2,158,356	0	0	For
Nuveen	0	2,096,333	0	Against
TIAA	0	2,082,414	0	Against
T. Rowe Price	0	1,968,864	0	Against
UBS	0	1,944,412	0	Against
TANG CAPITAL MANAGEMENT LLC	1,800,579	0	0	For
Wellington	0	1,747,751	0	Against
Invesco	0	1,736,826	0	Against

Showing the 25 largest of 324 asset managers. See all 324 in the interactive database.

2. A proposal to approve the Agreement and Plan of Merger, dated November 30, 2023 (as may be amended, modified or supplemented from time to time, the "Merger Agreement"), by and among ImmunoGen, Inc., a Massachusetts corporation ("ImmunoGen"), AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermedia

EXTRAORDINARY TRANSACTIONSCompany result: Passed

Combines 6 wordings of this item as funds reported it.

99% Passed · of votes cast

FOR 99%

FOR: 208,162,925AGAINST: 3,052,370

IMMUNOGEN INC.’s own tally for this item (“Proposal 1: Proposal to approve the Agreement and Plan of Merger, dated November 30, 2023 (as may be amended, modified or supplemented from time to time, the "Merger Agreement"), by and among ImmunoGen, AbbVie Inc., a De”): 208,162,925 for, 3,052,370 against — passed, per its Form 8-K filed 2024-01-31 (Item 5.07). Of all 265,842,000 outstanding shares: 78% for, 1% against (79% of the company cast a for/against vote).

The 91 asset managers below cast 100% of the shares they voted on this item FOR (65,924,647 for, 0 against).

FOR 96%

FOR: 65,924,647 (95.7%)ABSTAIN: 2,989,831 (4.3%)

Largest asset managers voting on “A proposal to approve the Agreement and Plan of Merger, dated November 30, 2023 (as may be amended, modified o” at IMMUNOGEN INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	24,977,242	0	For
BlackRock	11,709,780	0	For
Fidelity	5,280,817	0	For
JANUS INVESTMENT FUND	2,322,958	2,799,857	Abstain
State Street	2,607,273	0	For
TIAA	2,082,414	0	For
Charles Schwab	1,892,446	0	For
Principal	876,848	0	For
Invesco	812,324	0	For
T. Rowe Price	782,016	0	For
American Century	781,875	0	For
MERGER FUND	765,357	0	For
MUTUAL FUND SERIES TRUST	763,000	0	For
Artisan	737,364	0	For
AQR	725,907	0	For
Equitable	534,008	189,974	For
New York Life	693,003	0	For
ARBITRAGE FUNDS	625,852	0	For
FINANCIAL INVESTORS TRUST	573,839	0	For
Investment Managers Series Trust II	538,843	0	For
QUANTITATIVE MASTER SERIES LLC	436,447	0	For
First Trust	347,473	0	For
Direxion Shares ETF Trust	307,624	0	For
Jackson National	283,608	0	For
Dimensional	266,846	0	For

Showing the 25 largest of 91 asset managers. See all 91 in the interactive database.

3. A PROPOSAL TO ADJOURN THE SPECIAL MEETING TO A LATER DATE OR DATES, IF NECESSARY OR APPROPRIATE, INCLUDING TO SOLICIT ADDITIONAL PROXIES TO APPROVE THE MERGER AGREEMENT IF THERE ARE INSUFFICIENT VOTES TO APPROVE THE MERGER AGREEMENT AT THE TIME OF THE SPECIAL MEETING.

CORPORATE GOVERNANCE

87% fund support · no official result

FOR 83%13%

The 73 asset managers below cast 87% of the shares they voted on this item FOR (54,975,110 for, 8,495,515 against).

FOR: 54,975,110 (82.7%)AGAINST: 8,495,515 (12.8%)ABSTAIN: 3,005,700 (4.5%)

Largest asset managers voting on “A PROPOSAL TO ADJOURN THE SPECIAL MEETING TO A LATER DATE OR DATES, IF NECESSARY OR APPROPRIATE, INCLUDING TO ” at IMMUNOGEN INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	24,977,242	0	0	For
BlackRock	11,709,780	0	0	For
Fidelity	565,874	4,714,943	0	Against
JANUS INVESTMENT FUND	2,322,958	0	2,799,857	Abstain
State Street	3,386	2,603,887	0	Against
TIAA	2,082,414	0	0	For
Charles Schwab	1,892,446	0	0	For
Principal	876,848	0	0	For
Invesco	812,324	0	0	For
T. Rowe Price	0	782,016	0	Against
American Century	781,875	0	0	For
MERGER FUND	765,357	0	0	For
MUTUAL FUND SERIES TRUST	763,000	0	0	For
Artisan	737,364	0	0	For
AQR	725,907	0	0	For
Equitable	534,008	0	189,974	For
New York Life	693,003	0	0	For
Investment Managers Series Trust II	529,643	0	0	For
QUANTITATIVE MASTER SERIES LLC	436,447	0	0	For
First Trust	347,473	0	0	For
Direxion Shares ETF Trust	307,624	0	0	For
Dimensional	266,846	0	0	For
Lincoln Financial	17,076	202,793	0	Against
Brighthouse	79,806	114,300	15,869	Against
Voya	203,928	0	0	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

4. A proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, including to solicit additional proxies to approve the proposal to approve the Merger Agreement if there are insufficient votes to approve the Merger Agreement at the time of the Special Meeting.

CORPORATE GOVERNANCE

100% fund support · no official result

FOR 100%

The 18 asset managers below cast 100% of the shares they voted on this item FOR (2,438,143 for, 0 against).

FOR: 2,438,143 (100.0%)

Largest asset managers voting on “A proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, including to ” at IMMUNOGEN INC., 2023-2024
Asset manager	For	Vote
ARBITRAGE FUNDS	625,852	For
FINANCIAL INVESTORS TRUST	573,839	For
Jackson National	283,608	For
Calamos	191,840	For
John Hancock	185,711	For
PRIMECAP Odyssey Funds	183,200	For
JPMorgan	178,332	For
AltShares Trust	89,266	For
Bridge Builder Trust	78,607	For
Tema ETF Trust	17,626	For
Investment Managers Series Trust II	9,200	For
ETF Series Solutions	8,918	For
EA Series Trust	4,420	For
WILSHIRE MUTUAL FUNDS INC	3,543	For
NORTHERN LIGHTS FUND TRUST II	2,164	For
GPS Funds I	1,536	For
TRUST FOR PROFESSIONAL MANAGERS	395	For
CITY NATIONAL ROCHDALE FUNDS	86	For

5. Advisory Vote on Golden Parachutes

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

79% fund support · no official result

FOR 79%AGAINST 21%

The 7 asset managers below cast 79% of the shares they voted on this item FOR (2,379,472 for, 623,414 against).

FOR: 2,379,472 (79.2%)AGAINST: 623,414 (20.8%)

Largest asset managers voting on “Advisory Vote on Golden Parachutes” at IMMUNOGEN INC., 2023-2024
Asset manager	For	Against	Vote
Taconic Capital Advisors LP	1,143,348	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	530,844	400,462	For
Eversept Partners, LP	705,122	0	For
JPMorgan	0	221,172	Against
Desjardins Global Asset Management Inc.	0	1,780	Against
Convergence Investment Partners, LLC	158	0	For
OARSMAN CAPITAL, INC.	0	0	--

Largest IMMUNOGEN INC. shareholders voting in 2023-2024

Ranked by the number of IMMUNOGEN INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 265,842,000 shares outstanding at the time of that meeting.

Top IMMUNOGEN INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	New York Life	15.68%
2	Vanguard	9.61%
3	RA CAPITAL MANAGEMENT, L.P.	8.92%
4	BlackRock	7.60%
5	Redmile Group, LLC	6.18%
6	Fidelity	4.15%
7	State Street	3.70%
8	Janus Henderson	3.25%
9	Fairmount Funds Management LLC	2.23%
10	JANUS INVESTMENT FUND	1.93%

Reported IMMUNOGEN INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

IMMUNOGEN INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
The Vanguard Group	9.58%	13G

Percentages above are of 265,842,000 shares outstanding, as reported by IMMUNOGEN INC. on its Form 10-Q dated 2023-09-30 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IMMUNOGEN INC.’s 10-Q dated 2023-09-30. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At IMMUNOGEN INC.'s shareholder meeting held 2024-01-31, in the 2023-2024 proxy season, 337 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,159 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — A proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or… — the proposal failed with 43% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: IMMUNOGEN INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-01-31.

IMMUNOGEN INC. proxy season coverage: 2023-2024 (this page).